Treatment Patterns and Overall Survival among Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
Open Access
- 23 September 2019
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 15 (29) , 3381-3393
Abstract
Aim: To analyze treatment patterns and overall survival (OS) across time (2009-2014) among patients with unresected, stage III non-small-cell lung cancer (NSCLC). Patients & methods: Stage III NSCLC patients aged ≥65 years who initiated therapy were identified using SEER-Medicare data. Results: Among 4564 patients, 84% received chemotherapy (with or without radiotherapy), and 59% received chemoradiotherapy (CRT). Carboplatin + paclitaxel was the most frequent regimen. Median (interquartile range) OS among chemotherapy patients was 13.2 (6.0-28.9) months, and 14.8 (6.7-33.4) months among CRT patients. Among CRT patients, there was no difference in OS across years of CRT initiation. Conclusion: OS remained static across 2009-2014, indicating stagnancy in clinical outcomes for stage III NSCLC patients and a need for more effective therapeutic options.Keywords
Funding Information
- National Institute of Mental Health (R01MH098690, R00MH110343)
- AstraZeneca to conduct this study
This publication has 25 references indexed in Scilit:
- Comparison of SEER Treatment Data With Medicare ClaimsMedical Care, 2016
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain MetastasesCurrent Oncology, 2013
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Using claims‐based measures to predict performance status score in patients with lung cancerCancer, 2010
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United StatesLung Cancer, 2009
- Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group BJournal of Clinical Oncology, 2007
- Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital*Critical Care Medicine, 2006
- Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung CancerAnnals of Internal Medicine, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995